Author

Tadao ISHIDA

Institutions: Johnson & Johnson (United States), Japanese Red Cross Medical Center

Observed institutions: Johnson & Johnson (United States), Japanese Red Cross Medical Center

OpenAlex ID: A5159185366

First-in-human Study of Jnj-79635322 (jnj-5322), a Novel, Next-generation Trispecific Antibody, in Patients With Relapsed/refractory Multiple Myeloma: Initial Phase 1 Results

2026 · Rakesh POPAT, Cyrille TOUZEAU, et al. · Hematology Transfusion and Cell Therapy

Works count: 1

Citation count:

H-index:

I10-index: